U.S. Food and Drug Administration

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search

The U.S. Food and Drug Administration (FDA) is a regulatory commission that oversees food, drugs, medical devices, vaccines, tobacco products and more for the United States. To date, the FDA has not approved any drugs for the use of Myalgic Encephalomyelitis & Chronic Fatigue Syndrome (ME/CFS).

FDA activities on drug development for Myalgic Encephalomyelitis & Chronic Fatigue Syndrome[edit | edit source]

Webinar
Slides
Follow-up to the April 23, 2014 Webinar - Written Questions and Answers
Meeting Transcript

FDA response to Ampligen approval[edit | edit source]

Myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.